Title : Ongoing trials with trastuzumab in metastatic breast cancer.

Pub. Date : 2001

PMID : 11521725






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Another phase II study of trastuzumab plus paclitaxel, both given weekly, in 63 HER2-positive and -negative patients with metastatic breast cancer produced an overall response rate of 62% in HER2-positive and 44% in HER2-negative patients. Paclitaxel erb-b2 receptor tyrosine kinase 2 Homo sapiens
2 Another phase II study of trastuzumab plus paclitaxel, both given weekly, in 63 HER2-positive and -negative patients with metastatic breast cancer produced an overall response rate of 62% in HER2-positive and 44% in HER2-negative patients. Paclitaxel erb-b2 receptor tyrosine kinase 2 Homo sapiens
3 Another phase II study of trastuzumab plus paclitaxel, both given weekly, in 63 HER2-positive and -negative patients with metastatic breast cancer produced an overall response rate of 62% in HER2-positive and 44% in HER2-negative patients. Paclitaxel erb-b2 receptor tyrosine kinase 2 Homo sapiens